# T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant

> **NCT01621477** · PHASE2 · TERMINATED · sponsor: **St. Jude Children's Research Hospital** · enrollment: 34 (actual)

## Conditions studied

- Acute Lymphoblastic Leukemia
- Acute Myelocytic Leukemia
- Chronic Myelocytic Leukemia
- Juvenile Myelomonocytic Leukemia
- Myelodysplastic Syndrome
- Hodgkin or Non-Hodgkin Lymphoma
- Sarcoma, Myeloid

## Interventions

- **DRUG:** clofarabine
- **DRUG:** cytarabine
- **DRUG:** busulfan
- **DRUG:** Plerixafor
- **DRUG:** cyclophosphamide
- **DRUG:** antithymocyte globulin (rabbit)
- **BIOLOGICAL:** stem cells
- **DRUG:** Tacrolimus
- **DRUG:** mycophenolate mofetil

## Key facts

- **NCT ID:** NCT01621477
- **Lead sponsor:** St. Jude Children's Research Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-08
- **Primary completion:** 2015-12
- **Final completion:** 2015-12
- **Target enrollment:** 34 (ACTUAL)
- **Why stopped:** Study was terminated in August 2016 due to replacement by a new study.
- **Last updated:** 2017-02-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01621477

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01621477, "T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT01621477. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*